Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO-AD trial).

Knapp, Martin; King, Derek; Romeo, Renée; Adams, Jessica; Baldwin, Ashley; Ballard, Clive; Banerjee, Sube; Barber, Robert; Bentham, Peter; Brown, Richard G; Burns, Alistair; Dening, Tom; Findlay, David; Holmes, Clive; Johnson, Tony; Jones, Robert; Katona, Cornelius; Lindesay, James; Macharouthu, Ajay; McKeith, Ian; McShane, Rupert; O'Brien, John; Phillips, Patrick PJ; Sheehan, Bart; Howard, Robert

View / Open Files

Published version (PDF, 436Kb)

Authors

Knapp, Martin

King, Derek

Romeo, Renée

Adams, Jessica

Baldwin, Ashley

Ballard, Clive

Banerjee, Sube

Publication Date

2017-12

Journal Title

International journal of geriatric psychiatry

ISSN

0885-6230

Volume

Issue

Pages

1205-1216

Language

eng

Type

Article

Physical Medium

Print-Electronic

Metadata

Show full item record

Citation

Knapp, M., King, D., Romeo, R., Adams, J., Baldwin, A., Ballard, C., Banerjee, S., et al. (2017). Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO-AD trial).. International journal of geriatric psychiatry, 32 (12), 1205-1216. https://doi.org/10.1002/gps.4583

Keywords

Humans, Alzheimer Disease, Memantine, Piperidines, Indans, Cholinesterase Inhibitors, Activities of Daily Living, Double-Blind Method, Cognition, Quality of Life, Aged, Aged, 80 and over, Cost-Benefit Analysis, Health Care Costs, England, Wales, Female, Donepezil

Identifiers

External DOI: https://doi.org/10.1002/gps.4583

This record's URL: https://www.repository.cam.ac.uk/handle/1810/284952

Rights

Attribution 4.0 International

Licence URL: https://creativecommons.org/licenses/by/4.0/

Except where otherwise noted, this item's licence is described as Attribution 4.0 International